HiberCell, Inc.

A clinical-stage oncology company focused on developing first-in-class therapies that target adaptive-stress driven vulnerabilities. HiberCell aims to combat treatment resistance, cancer relapse, and metastasis by modulating adaptive stress pathways and enhancing anti-tumor immunity, differentiating itself through its unique approach to cancer treatment. The primary beneficiaries of HiberCell's innovations are cancer patients who face challenges with treatment resistance and disease recurrence.

No Data Available